|Articles|November 24, 2009

Beardsworth Selects OmniComm Systems TrialMaster Solution for the EDC of a Phase II Vaccine Study

Fort Lauderdale, FL

OmniComm Systems, Inc. announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm’s TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects.

"After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider,” said Michael J. O’Brien, Beardsworth President and CEO.

OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC utilizing OmniComm’s native, template matching, subsystem. Electronic exports from TrialMaster EDC to Beardsworth’s BNet portal will be achieved utilizing OmniComm’s new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.